ArticleImmunotherapy advances2023

Correction to: Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor.

PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.